Roche Delays CERA Oncology Filing Until 2009
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche is pushing back the timeline for filing its anti-anemia drug CERA, its continuous erythropoietin receptor activator, for the treatment of chemotherapy-associated anemia until 2009, the company reported Feb. 1
You may also be interested in...
Roche Suspends Phase II Mircera Study In Chemo-Induced Anemia
Firm halts recruitment of anemic non-small cell lung cancer patients due to an “imbalance” of deaths across study arms but maintains they are not related to the drug.
Roche Suspends Phase II Mircera Study In Chemo-Induced Anemia
Firm halts recruitment of anemic non-small cell lung cancer patients due to an “imbalance” of deaths across study arms but maintains they are not related to the drug.
Amgen Will Have Day In Court With Roche
The company also reports that sales of its TNF inhibitor Enbrel are “not meeting expectations.”